ZW171 is a mesothelin (MSLN)-targeting TCE currently in a global Phase 1 clinical study (NCT06523803) in a range of difficult-to-treat, MSLN-positive tumor models including ovarian, pancreatic ...

Additionally, we are proud to present the first preclinical data from our second program with Orano Med, targeting MSLN. The results show substantial uptake into MSLN-positive tumors, with limited ...

The meeting, scheduled for April 25-30 in Chicago, IL, will provide a platform for Context to present key data on CT-95, a bispecific T cell engager (TCE) targeting mesothelin (MSLN) and CD3 ...